Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Eli Lilly & Co. and AstraZeneca are shutting down Phase III studies of the Alzheimer’s treatment lanabecestat. An early look at data from two trials showed the drug was safe but unlikely to slow down the cognitive decline in people with early or mild forms of the disease. In 2014, Lilly had agreed to pay AstraZeneca up to $500 million to codevelop lanabecestat, a small molecule that blocks the activity of BACE, an enzyme that snips down amyloid-β. Lanabecestat adds to Lilly’s list of failed Alzheimer’s treatments, which include the internally developed BACE inhibitor LY2886721, the γ-secretase inhibitor semagacestat, and the anti-amyloid-β antibody solanezumab.
This article has been sent to the following recipient: